Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108424 | 0.83 | RAB9A (0.57) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL29429975 | 0.83 | RAB9A (0.57) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL28443608 | 0.78 | RAB9A (0.80) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL524926 | 0.78 | RAB9A (0.61) | RAB9ANPC1KDM4ELMNAPKM | |
| Phenanthrene SCHEMBL28773691 | 0.76 | NPC1 (0.50) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL6852547 | 0.75 | RAB9A (0.63) | RAB9ANPC1KDM4ELMNAPKM | |
| Formaldehyde SCHEMBL2137330 | 0.75 | NPC1 (0.53) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL6851972 | 0.75 | RAB9A (0.63) | RAB9ANPC1KDM4ELMNAPKM | |
| Formamide SCHEMBL9732751 | 0.75 | NPC1 (0.49) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL1163637 | 0.74 | NPC1 (0.62) | RAB9ANPC1KDM4ELMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071199-B1 | Kinase inhibitors as therapeutic agents | ABBOTT GMBH & CCO. KG (DE) | 2006-07-04 | — | — | US | claimed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | claimed |
| EP-1912948-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-09 | — | — | EP | disclosed |
| US-7915292-B2 | 2-{benzyl-[(6-methyl-2-phenyl-quinolin-3-yl)-phenyl-methyl]-amino}-N-(4-methyl-piperazin-1-yl)-acetamide; tuberculosis; antimycobacterial drugs; a tertiary nitrogen atom in the alpha position in the side chain attached to the 3-position of the quinoline nucleus to get fewer enantiomers possible | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080182855-A1 | Antibacterial Quinoline Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-31 | — | — | US | disclosed |
| EP-1912948-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7276487-B2 | 9a, 11-3C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2007014885-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| US-20050090460-A1 | 9a,11-3C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030227-A1 | 9a, 11-3C-BICYCLIC 9a-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6660718-B1 | Grampositive bacteria | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002043680-A1 | FIXATION OF CARBOHYDRATES TO FIBROUS MATERIALS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002043678-A2 | ENZYMATIC FIXATION OF DERIVATISED CARBOHYDRATES TO FIBROUS MATERIALS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2002-06-06 | — | — | WO | disclosed |
| EP-1191031-A1 | 3-MODIFIED LEUCOMYCIN DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | CYP3A7, CYP2C8, CYP51A1 | RAB9A 473/4885NPC1 364/4885KDM4E 224/4885 |
| US-20080182855-A1 | Antibacterial Quinoline Derivatives | NDUFB5, NQO2, MT-ND5 | RAB9A 950/4885NPC1 1076/4885KDM4E 4086/4885 |
| US-20050090460-A1 | 9a,11-3C-bicyclic 9a-azalide derivatives | CYP2C9, CYP2C19, UGT1A9 | RAB9A 126/4885NPC1 332/4885KDM4E 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.